Filtered By:
Procedure: Hemodialysis
Therapy: Dialysis

This page shows you your search results in order of date. This is page number 14.

Order by Relevance | Date

Total 299 results found since Jan 2013.

Soluble Urokinase Plasminogen Activator Receptor and Outcomes in Patients with Diabetes on Hemodialysis.
CONCLUSIONS: The association of soluble urokinase plasminogen activator receptor levels with outcomes persists in patients on hemodialysis. Additional study is warranted to characterize the underlying pathways of that association, which may yield opportunities to develop new therapeutic strategies. PMID: 28495863 [PubMed - as supplied by publisher]
Source: Clinical Journal of the American Society of Nephrology : CJASN - May 11, 2017 Category: Urology & Nephrology Authors: Drechsler C, Hayek SS, Wei C, Sever S, Genser B, Krane V, Meinitzer A, März W, Wanner C, Reiser J Tags: Clin J Am Soc Nephrol Source Type: research

A brief review of intradialytic hypotension with a focus on survival
Abstract Intradialytic hypotension (IDH), a common complication of ultrafiltration during hemodialysis therapy, is associated with high mortality and morbidity. IDH, defined as a nadir systolic blood pressure of less than 90 mm Hg on more than 30% of treatments, is a relevant definition and is correlated with mortality. Risk factors for IDH include patient demographics, anti‐hypertensive medication use, larger interdialytic weight gain, and dialysis prescription features as dialysate sodium, high ultrafiltration rate, and dialysate temperature. A high frequency of IDH events carries a substantial death risk. An ultrafilt...
Source: Seminars In Dialysis - May 1, 2017 Category: Hematology Authors: Jason A. Chou, Kamyar Kalantar ‐Zadeh, Anna T. Mathew Tags: INTRADIALYTIC HYPOTENSION: PERSPECTIVES IN CONTEMPORARY PRACTICE Source Type: research

Antithrombotic therapy in end ‐stage renal disease
Abstract The delicate balance of risk vs. benefit of using antiplatelet and antithrombotic agents in the general population is well established. The decision to use these agents in the end stage renal disease (ESRD) population remains complex and difficult. The concomitant association of a prothombotic state with high risk of bleeding in the ESRD population requires individualization and careful clinical judgment before implementing such therapy. There remains a paucity of clinical trials and lack of substantial evidence in literature for safe and effective use of antithrombotic drugs in patients with advanced chronic kidn...
Source: Hemodialysis International - April 1, 2017 Category: Hematology Authors: Svetha Chunduri, Jon E. Folstad, Tushar J. Vachharajani Tags: Review Article Source Type: research

Intradialytic Cardiac Magnetic Resonance Imaging to Assess Cardiovascular Responses in a Short-Term Trial of Hemodiafiltration and Hemodialysis
In conclusion, in this randomized, crossover study, there was no significant difference in the cardiovascular response to HDF or HD with cooled dialysate as assessed with intradialytic MRI.
Source: Journal of the American Society of Nephrology : JASN - March 31, 2017 Category: Urology & Nephrology Authors: Buchanan, C., Mohammed, A., Cox, E., Köhler, K., Canaud, B., Taal, M. W., Selby, N. M., Francis, S., McIntyre, C. W. Tags: Clinical Research Source Type: research

Cautious anticoagulation strategy in patients with dialysis-requiring end-stage kidney disease
To the Editor: We read with interest this manuscript which demonstrated in a large clinical registry that patients with chronic kidney disease with indications for anticoagulation were often treated subtherapeutically.1 A more aggressive approach was, therefore, advocated. We would like to point out that, while this study should be commended for including a large number of patients, it did not show data on the key clinical outcomes of stroke or bleeding. We feel, therefore, that a clear association cannot be made between low time in the therapeutic range (TTR) and any negative clinical outcome. In fact, paradoxically,...
Source: Heart - March 28, 2017 Category: Cardiology Authors: Behar, J. M., Forbes, S. H., Wragg, A., Sporton, S. Tags: Correspondence Source Type: research

Low-dose Apixaban May Be Safe Anti-stroke Option for Dialysis Patients Low-dose Apixaban May Be Safe Anti-stroke Option for Dialysis Patients
Low-dose apixaban achieves blood levels that appear to be safe and might be a “ reasonable alternative ” to warfarin for preventing stroke in patients with atrial fibrillation who are on hemodialysis, new research suggests.Reuters Health Information
Source: Medscape Critical Care Headlines - March 24, 2017 Category: Intensive Care Tags: Neurology & Neurosurgery News Source Type: news

High Stroke Volume Variation Is an Independent Predictor for Decreased Blood Pressure During Hemodialysis
Abstract It currently remains unclear whether stroke volume variation (SVV) before hemodialysis (HD) is an independent predictor of decreased blood pressure (BP) during HD. Fifty‐two patients were divided into two groups (Decreased BP during HD group: N = 10, Non‐decreased BP group: N = 42). Fractional shortening was lower, and mean arterial pressure (MAP) and SVV were higher in the Decreased BP during HD group. A multiple logistic regression analysis identified low fractional shortening, high MAP, and high SVV as independent predictors of decreased BP during HD. The areas under the ROC curves were as follows: 0.84...
Source: Therapeutic Apheresis and Dialysis - March 9, 2017 Category: Hematology Authors: Fumiki Yoshihara, Masatsugu Kishida, Koji Ogawa, Takayuki Nishigaki, Hironori Nakasaki, Azusa Ishizuka, Ryo Koezuka, Miki Matsuo, Teruyuki Hayashi, Satoko Nakamura Tags: Original Article Source Type: research

The effectiveness and safety of angiotensin-converting enzyme inhibition or receptor blockade in vascular diseases in patients with hemodialysis
Abstract: Patients with end-stage renal disease (ESRD) who are on hemodialysis have high risk of vascular diseases. Our study sought to examine whether angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin type 1 receptor blockers (ARBs) could reduce the frequencies of cardiovascular and cerebrovascular events in patients receiving hemodialysis using the medication possession ratio (MPR) method of analysis. This retrospective cohort study identified cases of ESRD with dialysis from the National Health Insurance Research Database between 1999 and 2006, and used Cox-regression methods to evaluate risk of poor outc...
Source: Medicine - March 1, 2017 Category: Internal Medicine Tags: Research Article: Observational Study Source Type: research

HDL Cholesterol Efflux Does Not Predict Cardiovascular Risk in Hemodialysis Patients
In conclusion, HDL cholesterol efflux capacity is not a prognostic cardiovascular risk marker in this cohort of patients with diabetes on hemodialysis.
Source: Journal of the American Society of Nephrology : JASN - February 27, 2017 Category: Urology & Nephrology Authors: Kopecky, C., Ebtehaj, S., Genser, B., Drechsler, C., Krane, V., Antlanger, M., Kovarik, J. J., Kaltenecker, C. C., Parvizi, M., Wanner, C., Weichhart, T., Säemann, M. D., Tietge, U. J. F. Tags: Brief Communications Source Type: research

Anticoagulation for atrial fibrillation in dialysis patients: What is known and what does the future hold?
The association between atrial fibrillation and stroke is well established, and in the general population, anticoagulation with warfarin can reduce the incidence of stroke by 60% with an acceptable bleeding risk.1,2 Patients who are on hemodialysis have an increased prevalence of atrial fibrillation, possibly secondary to comorbid conditions and hemodialysis itself causing dramatic swings in fluid and electrolytes and affecting cardiac dimensions.3 There are also substantially higher rates of ischemic stroke in this population attributable both to frequently co-occurring traditional stroke risk factors and to the increased...
Source: Heart Rhythm - February 18, 2017 Category: Cardiology Authors: Timothy M. Markman, Saman Nazarian Tags: Editorial Commentary Source Type: research

Editorial Commentary: Anticoagulation for atrial fibrillation in dialysis patients: What is known and what does the future hold?
The association between atrial fibrillation and stroke is well established and, in the general population, anticoagulation with warfarin can reduce the incidence of stroke by 60% with an acceptable bleeding risk.1, 2 Patients who are on hemodialysis have an increased prevalence of atrial fibrillation possibly secondary to comorbid conditions and hemodialysis itself causing dramatic swings in fluid and electrolytes and affecting cardiac dimensions.3 There are also substantially higher rates of ischemic stroke in this population attributable both to frequently co-occurring traditional stroke risk factors as well as the incre...
Source: Heart Rhythm - February 18, 2017 Category: Cardiology Authors: Timothy M. Markman, Saman Nazarian Source Type: research

Faster rate of blood volume change in pediatric hemodialysis patients impairs cardiac index
ConclusionThe cardiac index and stroke volume decreased significantly during the HD session. Patients with larger blood volume changes during the first 2  h of HD and at 4 h showed a significant decrease in cardiac index that did not recover at the completion of the HD treatment. Rate of fluid removal was the only significant risk factor for compromised cardiac index during HD. Conventional methods currently used for assisting fluid removal in HD ar e inadequate to assess hemodynamic changes.
Source: Pediatric Nephrology - January 1, 2017 Category: Urology & Nephrology Source Type: research

A contemporary evaluation of carotid endarterectomy outcomes in patients with chronic kidney disease in the United States.
Conclusions Patients with ESRD undergoing CEA had an increased risk of respiratory and septic complications, but not a higher risk of stroke compared to patients with normal renal function. The greatest risks of postoperative stroke, respiratory, and cardiac complications were found in patients with CKD. A diagnosis of ESRD and CKD were both found to significantly increase hospital mortality, length of stay and cost. Where clinicians typically consider ESRD patients the highest risk for CEA, further consideration should be given to patients with CKD not yet on dialysis as they had the higher risk of cardiac complications a...
Source: Vascular - December 31, 2016 Category: Surgery Authors: Patel AR, Dombrovskiy VY, Vogel TR Tags: Vascular Source Type: research

Comparison of the Safety and Effectiveness of Apixaban versus Warfarin in Patients with Severe Renal Impairment
ConclusionApixaban appears to be a reasonable alternative to warfarin in patients with severe renal impairment.This article is protected by copyright. All rights reserved.
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - December 31, 2016 Category: Drugs & Pharmacology Authors: Brooke E. Stanton, Naomi S. Barasch, Katie B. Tellor Tags: Original Research Article Source Type: research

Cognitive Impairment and Structural Neuroimaging Abnormalities Among Patients with Chronic Kidney Disease
Conclusion: Dialysis modality showed no association with cognitive impairment, although hemodialysis patients had more severe neuroimaging abnormalities. For the whole group, white matter hyperintensity, and ventricular and hippocampal atrophy, were independently associated with global cognitive impairment in chronic kidney disease patients.Kidney Blood Press Res 2016;41:986-996
Source: Kidney and Blood Pressure Research - December 17, 2016 Category: Urology & Nephrology Source Type: research